MetLife Investment Management’s Acacia Research ACTG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$94.6K Buy
20,309
+861
+4% +$4.14K ﹤0.01% 2789
2026
Q1
$93.5K Buy
+19,448
New +$82K ﹤0.01% 2570
2025
Q2
Sell
-4,012
Closed -$12.8K 2738
2025
Q1
$12.8K Sell
4,012
-18,035
-82% -$73.7K ﹤0.01% 2764
2024
Q4
$95.7K Buy
22,047
+14,797
+204% +$67K ﹤0.01% 2642
2024
Q3
$33.8K Sell
7,250
-14,819
-67% -$73.2K ﹤0.01% 2795
2024
Q2
$111K Buy
22,069
+2,291
+12% +$11.9K ﹤0.01% 2557
2024
Q1
$105K Sell
19,778
-413
-2% -$1.72K ﹤0.01% 2508
2023
Q4
$79.1K Hold
20,191
﹤0.01% 2695
2023
Q3
$73.7K Hold
20,191
﹤0.01% 2737
2023
Q2
$84K Buy
+20,191
New +$81.5K ﹤0.01% 2791
2022
Q1
Sell
-1,796
Closed -$9.21K 2729
2021
Q4
$9.21K Sell
1,796
-15,895
-90% -$85.8K ﹤0.01% 2496
2021
Q3
$120K Buy
+17,691
New +$108K ﹤0.01% 2358

Other funds holding ACTG

MetLife Investment Management's ACTG Position: Q2 2026 in Review

MetLife Investment Management increased its Acacia Research (ACTG) stake by 4.4% in Q2 2026, buying an estimated $4.14K and bringing the position to 20,309 shares worth $94.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2789.

MetLife Investment Management first reported a position in ACTG in Q3 2021 and has held it in 12 quarters since. The position peaked at $120K in Q3 2021. 123 funds tracked by Wall St. Rank hold ACTG as of Q2 2026.

  • MetLife Investment Management held 20,309 shares of Acacia Research worth $94.6K as of Q2 2026.
  • MetLife Investment Management bought 861 Acacia Research shares in Q2 2026, an estimated $4.14K.
  • Acacia Research made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2789 holding.
  • MetLife Investment Management first reported a position in Acacia Research in Q3 2021 and has held it in 12 quarters since.
  • MetLife Investment Management's Acacia Research position peaked at $120K in Q3 2021.
  • 123 funds tracked by Wall St. Rank held Acacia Research as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.